Omega-3 polyunsaturated fatty acids preserve retinal function in type 2 diabetic mice

Nutrition and Diabetes

Volumn 2, Issue JULY, 2012, Pages

  Sapieha, P ^a,b   Chen, J ^a   Stahl, A ^a,c   Seaward, M R ^a   Favazza, T L ^a   Juan, A M ^a   Hatton, C J ^a   Joyal, J S ^a   Krah, N M ^a   Dennison, R J ^a   Tang, J ^d   Kern, T S ^d   Akula, J D ^a   Smith, L E H ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITY OF FREIBURG   (Germany)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic retinopathy; Electroretinography; Omega 3 PUFAs

Indexed keywords

GLUCOSE; OMEGA 3 FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIETARY INTAKE; DYSLIPIDEMIA; ELECTRORETINOGRAPHY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RETINA CAPILLARY; VISION; VISUAL IMPAIRMENT;

EID: 84880533290     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2012.10     Document Type: Article

References (46)

1. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552-563.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
3. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527-532.
4. Engerman RL, Kern TS. Retinopathy in animal models of diabetes. Diabetes Metab Rev 1995; 11: 109-120.
5. Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005; 46: 2210-2218.
6. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102: 783-791.
7. Gastinger MJ, Kunselman AR, Conboy EE, Bronson SK, Barber AJ. Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita diabetic mice. Invest Ophthalmol Vis Sci 2008; 49: 2635-2642.
8. Sapieha P, Hamel D, Shao Z, Rivera JC, Zaniolo K, Joyal JS et al. Proliferative retinopathies: angiogenesis that blinds. Int J Biochem Cell Biol 2010; 42: 5-12.
9. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-244.
10. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-918.
11. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697.
12. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 2005; 24: 87-138.
13. Fetterman Jr JW, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm 2009; 66: 1169-1179.
14. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007; 13: 868-873.
15. Sapieha P, Stahl A, Chen J, Seaward MR, Willett KL, Krah NM et al. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of {omega}-3 polyunsaturated fatty acids. Sci Transl Med 2011; 3: 69ra12.
16. Stahl A, Sapieha P, Connor KM, Sangiovanni JP, Chen J, Aderman CM et al. Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ Res 2010; 107: 495-500.
17. SanGiovanni JP, Chew EY, Clemons TE, Davis MD, Ferris 3rd FL, Gensler GR et al. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. Arch Ophthalmol 2007; 125: 671-679.
18. Abbatecola AM, Evans W, Paolisso G. PUFA supplements and type 2 diabetes in the elderly. Curr Pharm Des 2009; 15: 4126-4134.
19. Akula JD, Mocko JA, Benador IY, Hansen RM, Favazza TL, Vyhovsky TC et al. The neurovascular relation in oxygen-induced retinopathy. Mol Vis 2008; 14: 2499-2508.
20. Hood DC, Birch DG. A computational model of the amplitude and implicit time of the b-wave of the human ERG. Vis Neurosci 1992; 8: 107-126.
21. Lamb TD, Pugh Jr EN. A quantitative account of the activation steps involved in phototransduction in amphibian photoreceptors. J Physiol 1992; 449: 719-758.
22. Wurziger K, Lichtenberger T, Hanitzsch R. On-bipolar cells and depolarising thirdorder neurons as the origin of the ERG-b-wave in the RCS rat. Vision Res 2001; 41: 1091-1101.
23. Robson JG, Frishman LJ. Response linearity and kinetics of the cat retina: the bipolar cell component of the dark-adapted electroretinogram. Vis Neurosci 1995; 12: 837-850.
24. Akula JD, Lyubarsky AL, Naarendorp F. The sensitivity and spectral identity of the cones driving the b-wave of the rat electroretinogram. Vis Neurosci 2003; 20: 109-117.
25. Akula JD, Mocko JA, Moskowitz A, Hansen RM, Fulton AB. The oscillatory potentials of the dark-adapted electroretinogram in retinopathy of prematurity. Invest Ophthalmol Vis Sci 2007; 48: 5788-5797.
26. Kern TS, Engerman RL. A mouse model of diabetic retinopathy. Arch Ophthalmol 1996; 114: 986-990.
27. Kowluru RA, Engerman RL, Kern TS. Diabetes-induced metabolic abnormalities in myocardium: effect of antioxidant therapy. Free Radic Res 2000; 32: 67-74.
28. Zheng L, Du Y, Miller C, Gubitosi-Klug RA, Ball S, Berkowitz BA et al. Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 2007; 50: 1987-1996.
29. Shirao Y, Kawasaki K. Electrical responses from diabetic retina. Prog Retin Eye Res 1998; 17: 59-76.
30. Li Q, Zemel E, Miller B, Perlman I. Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp Eye Res 2002; 74: 615-625.
31. Hancock HA, Kraft TW. Oscillatory potential analysis and ERGs of normal and diabetic rats. Invest Ophthalmol Vis Sci 2004; 45: 1002-1008.
32. Qin Q, Patil KA, Gronert K, Sharma SC. Neuroprotectin D1 inhibits retinal ganglion cell death following axotomy. Prostaglandins Leukot Essent Fatty Acids 2008; 79: 201-207.
33. Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, Romanelli AJ et al. n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner. Diabetes 2007; 56: 1034-1041.
34. Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 1987; 237: 885-888.
35. Oshitari T, Hanawa K, Adachi-Usami E. Changes of macular and RNFL thicknesses measured by Stratus OCT in patients with early stage diabetes. Eye (Lond) 2009; 23: 884-889.
36. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008; 30: 65-84.
37. Kowluru RA, Koppolu P. Diabetes-induced activation of caspase-3 in retina: effect of antioxidant therapy. Free Radic Res 2002; 36: 993-999.
38. Mohr S, Xi X, Tang J, Kern TS. Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients. Diabetes 2002; 51: 1172-1179.
39. Dorrell MI, Aguilar E, Jacobson R, Yanes O, Gariano R, Heckenlively J et al. Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. J Clin Invest 2009; 119: 611-623.
40. Stahl A, Krohne TU, Sapieha P, Chen J, Hellstrom A, Chew E et al. Lipid metabolites in the pathogenesis and treatment of neovascular eye disease. Br J Ophthalmol 2011; 95: 1496-1501.
41. Shue EH, Carson-Walter EB, Liu Y, Winans BN, Ali ZS, Chen J et al. Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models. BMC Neurosci 2008; 9: 29.
42. Keuschnigg J, Henttinen T, Auvinen K, Karikoski M, Salmi M, Jalkanen S. The prototype endothelial marker PAL-E is a leukocyte trafficking molecule. Blood 2009; 114: 478-484.
43. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipidactivated nuclear receptors. Nature 2008; 454: 470-477.
44. Fehm HL, Kern W, Peters A. The selfish brain: competition for energy resources. Prog Brain Res 2006; 153: 129-140.
45. Pardridge WM. Transport of insulin-related peptides and glucose across the blood-brain barrier. Ann NY Acad Sci 1993; 692: 126-137.
46. Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci 2008; 9: 36-45.